Association Between Matrix Metalloproteinase-3 Activity and Glomerular Filtration Rate and Albuminuria Status in Patients With Type 2 Diabetes Mellitus
- PMID: 29421776
Association Between Matrix Metalloproteinase-3 Activity and Glomerular Filtration Rate and Albuminuria Status in Patients With Type 2 Diabetes Mellitus
Abstract
Introduction: Diabetic nephropathy is pictured as matrix accumulation and thickening of glomerular basal membrane. Matrix metalloproteinases (MMPs) are major proteases involved in extracellular matrix degradation. Moreover, plasminogen activator inhibitor-1 (PAI-1) primarily regulates plasmin dependent proteolysis. It plays a role in renal fibrosis causing extracellular matrix accumulation through inhibition of plasmin-dependent extracellular matrix degradation. This study investigated PAI-1 serum level and MMP-3 activity and their correlation with glomerular filtration rate in patients with diabetes mellitus.
Materials and methods: In a case-control design, serum PAI-1 concentrations and MMP-3 activity were measured in 80 patients with normoalbuminuria, microalbuminuria, and macroalbuminuria. Receiver operating characteristics curve analysis was used to assess the diagnostic accuracy of MMP-3 activity in discriminating albuminuria.
Results: In the patients with microalbuminuria, serum PAI-1 levels were higher compared with macroalbuminuric patients (P < .001). The patients with macroalbuminuria exhibited a significantly lower MMP-3 activity than the patients with microalbuminuria and normoalbuminuria (P < .001). No significant correlation was found between serum MMP-3 activity and serum PAI-1 levels in those with normoalbuminuria, microalbuminuria, and macroalbuminuria. The MMP-3 activity had a strong positive correlation with estimated glomerular filtration (r = 0.853, P < .001).
Conclusions: We found that there was a positive correlation between glomerular filtration rate and MMP-3 activity in diabetic patients. This concludes that MMP-3 may have a role in the pathogenesis of diabetic nephropathy progressions towards macroalbuminuria, and therefore, MMP-3 activity may be used in evaluating albuminuria status.
Similar articles
-
Higher serum betatrophin level in type 2 diabetes subjects is associated with urinary albumin excretion and renal function.Cardiovasc Diabetol. 2016 Jan 7;15:3. doi: 10.1186/s12933-015-0326-9. Cardiovasc Diabetol. 2016. PMID: 26739836 Free PMC article.
-
Albuminuria and reduced glomerular filtration rate for predicting the renal outcomes in type 2 diabetic patients.Nephrology (Carlton). 2015 Aug;20(8):531-8. doi: 10.1111/nep.12446. Nephrology (Carlton). 2015. PMID: 25773273
-
Urinary heme oxygenase-1 as a potential biomarker for early diabetic nephropathy.Nephrology (Carlton). 2017 Jan;22(1):58-64. doi: 10.1111/nep.12719. Nephrology (Carlton). 2017. PMID: 26733347
-
Normoalbuminuric diabetic kidney disease.Front Med. 2017 Sep;11(3):310-318. doi: 10.1007/s11684-017-0542-7. Epub 2017 Jul 18. Front Med. 2017. PMID: 28721497 Review.
-
The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients.Diabetes Metab. 2012 Oct;38(4):291-7. doi: 10.1016/j.diabet.2012.04.001. Epub 2012 May 22. Diabetes Metab. 2012. PMID: 22622176 Review.
Cited by
-
Development of Biomarkers and Molecular Therapy Based on Inflammatory Genes in Diabetic Nephropathy.Int J Mol Sci. 2021 Sep 15;22(18):9985. doi: 10.3390/ijms22189985. Int J Mol Sci. 2021. PMID: 34576149 Free PMC article. Review.
-
lncRNA MALAT1 Promotes Renal Fibrosis in Diabetic Nephropathy by Targeting the miR-2355-3p/IL6ST Axis.Front Pharmacol. 2021 Apr 29;12:647650. doi: 10.3389/fphar.2021.647650. eCollection 2021. Front Pharmacol. 2021. PMID: 33995063 Free PMC article.
-
Aortic Aneurysms, Chronic Kidney Disease and Metalloproteinases.Biomolecules. 2021 Jan 30;11(2):194. doi: 10.3390/biom11020194. Biomolecules. 2021. PMID: 33573220 Free PMC article. Review.
-
Assessment of the concentration of selected metalloproteinases (MMP-2, MMP-3, MMP-9 and MMP-13) in patients with ulcers as a complication of type 2 diabetes.Postepy Dermatol Alergol. 2022 Feb;39(1):59-65. doi: 10.5114/ada.2020.100737. Epub 2020 Nov 13. Postepy Dermatol Alergol. 2022. PMID: 35369620 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous